Vericel to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference
November 10 2022 - 8:00AM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies
for the sports medicine and severe burn care markets, today
announced that Company leadership will present at the upcoming
Canaccord Genuity MedTech, Diagnostics, and Digital Health &
Service Forum and the Stephens Annual Investment Conference.
Nick Colangelo, President and CEO will present at the CG
MedTech, Diagnostics, and Digital Health & Service Forum at
10:00 a.m. ET on Thursday, November 17, 2022. Joe Mara, CFO will
also present on Thursday, November 17, 2022 at 11:00 a.m. ET at the
Stephens Annual Investment Conference.
Webcasts of both presentations will be available on the Investor
Relations section of the Vericel Corporation website at:
http://investors.vcel.com.
About Vericel CorporationVericel is a leader in
advanced therapies for the sports medicine and severe burn care
markets. The company markets two cell therapy products in the
United States. MACI® (autologous cultured chondrocytes on porcine
collagen membrane) is an autologous cellularized scaffold product
indicated for the repair of symptomatic, single or multiple
full-thickness cartilage defects of the knee with or without bone
involvement in adults. Epicel® (cultured epidermal autografts) is a
permanent skin replacement for the treatment of patients with deep
dermal or full thickness burns greater than or equal to 30% of
total body surface area. The company also holds an exclusive
license for North American commercial rights to NexoBrid®, a
registration-stage biological orphan product for debridement of
severe thermal burns. For more information, please visit
www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel
Corporation. NexoBrid® is a registered trademark of MediWound Ltd.
and is used under license to Vericel Corporation. © 2022 Vericel
Corporation. All rights reserved.
Investor Contact:Eric Burnsir@vcel.com+1 (734)
418-4411
Media Contact:Julie Downsmedia@vcel.com
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024